Mary O'Brien, MD

Trials

Studies that name Mary O'Brien, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:22 UTC. Open this list on ClinicalTrials.gov

• Ph3
  NCT02129699 · Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy

  ETOP IBCSG Partners Foundation · terminated · Lung Cancer Non-small Cell Stage IV · study chair
• Ph2/Ph3
  NCT01208064 · Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy

  European Organisation for Research and Treatment of Cancer - EORTC · terminated · Lung Cancer · principal investigator
• Ph2
  NCT00458913 · Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma

  European Organisation for Research and Treatment of Cancer - EORTC · completed · Malignant Mesothelioma · study chair
• Ph2
  NCT00388960 · Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer

  Celgene · completed · Small Cell Lung Cancer · principal investigator
• N/A
  NCT00005071 · Diagnosis and Treatment Planning in Patients Suspected of Having Lung Cancer

  Royal Marsden NHS Foundation Trust · unknown · Lung Cancer · study chair

Grants

NIH projects from RePORTER, fetched 2026-11-12 12:22 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.